Elicio Therapeutics Inc ELTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:49 PM EDT
10.10quote price arrow up+0.72 (+7.68%)
Volume
34,942
52 week range
2.96 - 24.39
Loading...
  • Open9.96
  • Day High10.38
  • Day Low9.50
  • Prev Close9.38
  • 52 Week High24.39
  • 52 Week High Date06/02/23
  • 52 Week Low2.96
  • 52 Week Low Date02/07/24

Key Stats

  • Market Cap103.339M
  • Shares Out10.23M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.78
  • YTD % Change22.18

KEY STATS

  • Open9.96
  • Day High10.38
  • Day Low9.50
  • Prev Close9.38
  • 52 Week High24.39
  • 52 Week High Date06/02/23
  • 52 Week Low2.96
  • 52 Week Low Date02/07/24
  • Market Cap103.339M
  • Shares Out10.23M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.78
  • YTD % Change22.18

RATIOS/PROFITABILITY

  • EPS (TTM)-8.81
  • P/E (TTM)-1.15
  • Fwd P/E (NTM)-2.91
  • EBITDA (TTM)-35.363M
  • ROE (TTM)-127.64%
  • Revenue (TTM)-
  • Gross Margin (TTM)90.32%
  • Net Margin (TTM)-4,456.97%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Elicio Therapeutics Inc

 

Profile

MORE
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial...
Julian Adams Ph.D.
Chairman of the Board
Robert Connelly
President, Chief Executive Officer, Director
Brian Piekos
Chief Financial Officer
Christopher Haqq M.D., Ph.D.
Executive Vice President - Head of Research and Development, Chief Medical Officer
Address
451 D Street, 5Th Floor
Boston, MA
02459
United States

Top Peers

SYMBOLLASTCHG%CHG
ANIX
Anixa Biosciences Inc
2.85-0.06-1.89%
IOBT
IO Biotech Inc
1.40UNCHUNCH
SGMT
Sagimet Biosciences Inc
4.61-0.14-2.95%
PASG
Passage Bio Inc
1.34UNCHUNCH
MIST
Milestone Pharmaceuticals Inc
1.75UNCHUNCH